PRIMARY STUDY
A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment
Key Findings: Renal function did not affect the metabolism of one dose of 200mg of cannabidiol (CBD) in patients with baseline renal dysfunction. Overall, it was well tolerated and with only mild adverse effects reported.
Type of Study: Clinical Trial
Study Sample Size: 16
Study Result: Positive
Research Location(s): United Kingdom, United States
Year of Pub: 2020
Cannabinoids Studied: Cannabidiol (CBD), Pharma CBD
Phytocannabinoid Source: Isolate
Chemotype: Chemotype III
Receptors Studied: CB1, GPCR 55, TRPV1, GPCR
Dosage: CBD(Epidiolex) (200mg once by mouth)
Route of Administration: Oral (Ingestion)
Citation: Tayo B, et al. A Phase I, Open-Label, Parallel-Group, Single-Dose Trial of the Pharmacokinetics, Safety, and Tolerability of Cannabidiol in Subjects with Mild to Severe Renal Impairment. Clin Pharmacokinet. 2020; 59:747-755. doi: 10.1007/s40262-019-00841-6
Authors: Tayo B, Taylor L, Sahebkar F, Morrison G
